keyword
https://read.qxmd.com/read/38507813/targeting-neuroinflammation-by-pharmacologic-downregulation-of-inflammatory-pathways-is-neuroprotective-in-protein-misfolding-disorders
#1
JOURNAL ARTICLE
Sydney J Risen, Sean W Boland, Sadhana Sharma, Grace M Weisman, Payton M Shirley, Amanda S Latham, Arielle J D Hay, Vincenzo S Gilberto, Amelia D Hines, Stephen Brindley, Jared M Brown, Stephanie McGrath, Anushree Chatterjee, Prashant Nagpal, Julie A Moreno
Neuroinflammation plays a crucial role in the development of neurodegenerative protein misfolding disorders. This category of progressive diseases includes, but is not limited to, Alzheimer's disease, Parkinson's disease, and prion diseases. Shared pathogenesis involves the accumulation of misfolded proteins, chronic neuroinflammation, and synaptic dysfunction, ultimately leading to irreversible neuronal loss, measurable cognitive deficits, and death. Presently, there are few to no effective treatments to halt the advancement of neurodegenerative diseases...
March 20, 2024: ACS Chemical Neuroscience
https://read.qxmd.com/read/38465343/transplantation-of-human-neural-stem-cell-prevents-symptomatic-motor-behavior-disability-in-a-rat-model-of-parkinson-s-disease
#2
JOURNAL ARTICLE
Fen Wang, Xiao-Yu Cheng, Yu-Ting Zhang, Qing-Ran Bai, Xiao-Qi Zhang, Xi-Cai Sun, Quan-Hong Ma, Xiong-Fei Zhao, Chun-Feng Liu
Parkinson's disease (PD) is a ubiquitous brain cell degeneration disease and presents a significant therapeutic challenge. By injecting 6-hydroxydopamine (6-OHDA) into the left medial forebrain bundle, rats were made to exhibit PD-like symptoms and treated by intranasal administration of a low-dose (2 × 105 ) or high-dose (1 × 106 ) human neural stem cells (hNSCs). Apomorphine-induced rotation test, stepping test, and open field test were implemented to evaluate the motor behavior and high-performance liquid chromatography was carried out to detect dopamine (DA), 3,4-dihydroxyphenylacetic acid (DOPAC), serotonin, and 5-hydroxyindole-3-acetic acid in the striatum of rats...
2024: Open Life Sciences
https://read.qxmd.com/read/38399387/optimization-of-pramipexole-loaded-in-situ-thermosensitive-intranasal-gel-for-parkinson-s-disease
#3
JOURNAL ARTICLE
Rushi Trivedi, Vahid Vikram Minglani, Ahmed M El-Gazzar, Gaber El-Saber Batiha, Mohamed H Mahmoud, Mitesh Patel, Meenakshi Patel
The objective of the present work was to develop and optimize an intranasal in situ gel of Pramipexole dihydrochloride for enhanced drug delivery, better patient acceptability, and possible proper treatment of Parkinson's disease. Preliminary studies were performed to select formulation components and identify key variables affecting the formulation. The optimization of the in situ gelling system of Pramipexole dihydrochloride was achieved by applying 32 full factorial design using Design-Expert® software (Stat-Ease 9...
January 29, 2024: Pharmaceuticals
https://read.qxmd.com/read/38386974/lipid-and-transcriptional-regulation-in-a-parkinson-s-disease-mouse-model-by-intranasal-vesicular-and-hexosomal-plasmalogen-based-nanomedicines
#4
JOURNAL ARTICLE
Yu Wu, Jieli Wang, Yuru Deng, Borislav Angelov, Takehiko Fujino, Md Shamim Hossain, Angelina Angelova
Plasmalogens (vinyl-ether phospholipids) are an emergent class of lipid drugs against various diseases involving neuro-inflammation, oxidative stress, mitochondrial dysfunction, and altered lipid metabolism. They can activate neurotrophic and neuroprotective signaling pathways but low bioavailabilities limit their efficiency in curing neurodegeneration. Here we created liquid crystalline lipid nanoparticles (LNPs) for protection and non-invasive intranasal delivery of purified scallop-derived plasmalogens. Our in vivo results with a transgenic mouse Parkinson's disease (PD) model (characterized by motor impairments and α-synuclein deposition) demonstrated the crucial importance of LNP composition, which determines the self-assembled nanostructure type...
February 22, 2024: Advanced Healthcare Materials
https://read.qxmd.com/read/38380382/reduced-menthol-sensitivity-in-a-prodromal-parkinson-s-disease-model-induced-by-intranasal-rotenone-treatment
#5
JOURNAL ARTICLE
Hajime Sato, Keitaro Satoh, Kazunori Nozaki, Misato Yugawa, Takafumi Kato, Hiroki Toyoda, Ayano Katagiri, Naoto Suda, Kazunori Adachi
Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor symptoms, and it is associated with several prodromal non-motor symptoms, including an impaired sense of smell, taste and touch. We previously reported that bitter taste impairments occur independently of olfactory impairments in an early-stage PD animal model using short-term intranasal rotenone-treated mice. Cool temperatures also affect bitter taste perception, but it remains unclear whether or not bitter taste impairments result from an altered sensitivity for intraoral cool stimuli...
2024: Frontiers in Cellular Neuroscience
https://read.qxmd.com/read/38367134/the-synergistic-effect-study-of-lipopolysaccharide-lps-and-a53t-%C3%AE-synuclein-intranasal-lps-exposure-on-the-a53t-%C3%AE-synuclein-transgenic-mouse-model-of-parkinson-s-disease
#6
JOURNAL ARTICLE
Qing He, Shuzhen Zhang, Jian Wang, Tengfei Ma, Ding Ma, Li Wu, Mengxi Zhou, Lei Zhao, Yajing Chen, Jianren Liu, Wei Chen
Aging and interactions between genetic and environmental factors are believed to be involved the chronic development of Parkinson's disease (PD). Among PD patients, abnormally aggregated α-synuclein is a major component of the Lewy body. Generally, the intranasal route is believed to be a gate way to the brain, and it assists environmental neurotoxins in entering the brain and is related to anosmia during early PD. The current study applies the chronic intranasal application of lipopolysaccharides (LPS) in 4-, 8-, 12- and 16-month-old A53T-α-synuclein (A53T-α-Syn) transgenic C57BL/6 mice at 2-day intervals for a 2-month period, for evaluating the behavioral, pathological, and biochemical changes and microglial activation in these animals...
February 17, 2024: Molecular Neurobiology
https://read.qxmd.com/read/38058006/nanocarrier-mediated-curcumin-delivery-an-adjuvant-strategy-for-cns-disease-treatment
#7
REVIEW
Sandip Godse, Lina Zhou, Swarna Sakshi, Bhupesh Singla, Udai P Singh, Santosh Kumar
Neurological disorders are a major global challenge, which counts for a substantial slice of disease burden around the globe. In these, the challenging landscape of central nervous system (CNS) diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and neuro-AIDS, demands innovative and novel therapeutic approaches. Curcumin, a versatile natural compound with antioxidant and anti-inflammatory properties, shows great potential as a CNS adjuvant therapy. However, its limited bioavailability and suboptimal permeability to the blood-brain barrier (BBB) hamper the therapeutic efficacy of curcumin...
December 6, 2023: Experimental Biology and Medicine
https://read.qxmd.com/read/38043777/harnessing-the-neuroprotective-effect-of-oral-administration-of-benfotiamine-in-mptp-induced-parkinson-s-disease-in-rats
#8
JOURNAL ARTICLE
Bushra Bashir, Swati Mittal, A Muthukumar, Sukriti Vishwas, Narendra Kumar Pandey, Monica Gulati, Gaurav Gupta, Muralikrishnan Dhanasekaran, Puneet Kumar, Harish Dureja, Francisco Veiga, Ana Claudia Paiva-Santos, Jon Adams, Kamal Dua, Sachin Kumar Singh
The study was performed to evaluate the neuroprotective effects of Benfotiamine (BFT) in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease (PD) in rats. The rats were given daily doses of BFT (100mg/kg, 200mg/kg) through oral administration for 42 days. The rats were given a single bilateral dosage of MPTP (0.1 mg/nostril) intranasally once before the drug treatment to induce PD. On day 42, the animals were subjected to various behavioral paradigms. Post-treatment with BFT for 42 days significantly improved the motor and nonmotor fluctuations of MPTP...
December 1, 2023: European Journal of Pharmacology
https://read.qxmd.com/read/37921949/purple-pitanga-extract-eugenia-uniflora-attenuates-oxidative-stress-induced-by-mptp
#9
JOURNAL ARTICLE
Eduarda Monteiro Fidelis, Anne Suely P Savall, Jhuly Dornelles Mello, Caroline Brandão Quines, Antônio Alvenir Comis-Neto, Tuane Bazanella Sampaio, Cristiane Casagrande Denardin, Daiana Silva de Ávila, Suzan Gonçalves Rosa, Simone Pinton
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been widely used due to its specific and reproducible neurotoxic effect on the nigrostriatal system, being considered a convenient model of dopaminergic neurodegeneration to study interventions therapeutics. The purple pitanga (Eugenia uniflora) is a polyphenol-rich fruit with antioxidant and antidepressant properties, among others. Therefore, this study investigated the effect of purple pitanga extract (PPE) on acute early oxidative stress induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats...
November 3, 2023: Metabolic Brain Disease
https://read.qxmd.com/read/37895895/liposome-derived-nanosystems-for-the-treatment-of-behavioral-and-neurodegenerative-diseases-the-promise-of-niosomes-transfersomes-and-ethosomes-for-increased-brain-drug-bioavailability
#10
REVIEW
Patrícia C Pires, Ana Cláudia Paiva-Santos, Francisco Veiga
Psychiatric and neurodegenerative disorders are amongst the most prevalent and debilitating diseases, but current treatments either have low success rates, greatly due to the low permeability of the blood-brain barrier, and/or are connected to severe side effects. Hence, new strategies are extremely important, and here is where liposome-derived nanosystems come in. Niosomes, transfersomes, and ethosomes are nanometric vesicular structures that allow drug encapsulation, protecting them from degradation, and increasing their solubility, permeability, brain targeting, and bioavailability...
October 8, 2023: Pharmaceuticals
https://read.qxmd.com/read/37893474/cognitive-impairment-in-parkinson-s-disease-an-updated-overview-focusing-on-emerging-pharmaceutical-treatment-approaches
#11
REVIEW
Yildiz Degirmenci, Efthalia Angelopoulou, Vasiliki Epameinondas Georgakopoulou, Anastasia Bougea
Cognitive impairment in patients with Parkinson's disease (PD) is one of the commonest and most disabling non-motor manifestations during the course of the disease. The clinical spectrum of PD-related cognitive impairment includes subjective cognitive decline (SCD), mild cognitive impairment (MCI) and PD dementia (PDD). As the disease progresses, cognitive decline creates a significant burden for the family members and/or caregivers of patients with PD, and has a great impact on quality of life. Current pharmacological treatments have demonstrated partial efficacy and failed to halt disease progression, and novel, effective, and safe therapeutic strategies are required...
October 1, 2023: Medicina
https://read.qxmd.com/read/37865662/dopaminergic-neurodegeneration-in-the-substantia-nigra-is-associated-with-olfactory-dysfunction-in-mice-models-of-parkinson-s-disease
#12
JOURNAL ARTICLE
Yu Yuan, Xizhen Ma, Xiaoqing Mi, Le Qu, Meiyu Liang, Mengyu Li, Youcui Wang, Ning Song, Junxia Xie
Olfactory dysfunction represents a prodromal stage in Parkinson's disease (PD). However, the mechanisms underlying hyposmia are not specified yet. In this study, we first observed an early olfactory dysfunction in mice with intragastric rotenone administration, consistent with dopaminergic neurons loss and α-synuclein pathology in the olfactory bulb. However, a much severer olfactory dysfunction was observed without severer pathology in olfactory bulb when the loss of dopaminergic neurons in the substantia nigra occurred...
October 21, 2023: Cell Death Discovery
https://read.qxmd.com/read/37833807/mesenchymal-stromal-cell-biotherapy-for-parkinson-s-disease-premotor-symptoms
#13
REVIEW
Jinmei Sun, Wei Zhang, Zheng Zachory Wei, Xiaopeng Song, Liu Jian, Feng Jiang, Shuanglin Wang, Haibo Li, Yongbo Zhang, Houzhen Tuo
Parkinson's disease (PD) is a neurodegenerative disorder with motor deficits due to nigrostriatal dopamine depletion and with the non-motor/premotor symptoms (NMS) such as anxiety, cognitive dysfunction, depression, hyposmia, and sleep disorders. NMS is presented in at least one-fifth of the patients with PD. With the histological information being investigated, stem cells are shown to provide neurotrophic supports and cellular replacement in the damaging brain areas under PD conditions. Pathological change of progressive PD includes degeneration and loss of dopaminergic neurons in the substantia nigra of the midbrain...
October 13, 2023: Chinese Neurosurgical Journal
https://read.qxmd.com/read/37787159/design-and-evaluations-of-a-nanostructured-lipid-carrier-loaded-with-dopamine-hydrochloride-for-intranasal-bypass-drug-delivery-in-parkinson-s-disease
#14
JOURNAL ARTICLE
Neha Sl, Ashwini Kumar Mishra, Laxmi Rani, Shweta Paroha, Hitesh Kumar Dewangan, Pravat Kumar Sahoo
Aim- The goal of this study is to optimization and evaluation of dopamine-loaded NLC (NLC-DOPA) for achieve dopamine concentrations into brain for treatment of Parkinson's disease which causes progressive neuronal death. Method- NLC-DOPA prepared by homogenization method using solid lipids (Cholesterol and Soya lecithin), liquid lipid (Oleic acid) and surfactant (Poloxamer- 188) as major excipients, optimized by central composite design using design expert-13 software. The optimized formulations were characterized by particle size, zeta potential, entrapment efficiency, SEM, TEM, FTIR, DSC, XRD, stability study and in-vitro drug release...
October 3, 2023: Journal of Microencapsulation
https://read.qxmd.com/read/37783252/carboxymethyl-chitosan-dopamine-conjugates-synthesis-and-evaluation-for-intranasal-anti-parkinson-therapy
#15
JOURNAL ARTICLE
Sante Di Gioia, Giuseppe Fracchiolla, Stefania Cometa, Filippo Maria Perna, Andrea Francesca Quivelli, Giuseppe Trapani, Valeria Daniello, Concetta Nobile, Md Niamat Hossain, Adriana Trapani, Massimo Conese
With respect to the Parkinson's disease (PD), herein, we aimed at synthetizing and characterizing two novel macromolecular conjugates where dopamine (DA) was linked to N,O-carboxymethyl chitosan or O-carboxymethyl chitosan, being both conjugates obtained from an organic solvent free synthetic procedure. They were characterized by FT-IR, 1 H NMR spectroscopies, whereas thermal analysis (including Differential Scanning Calorimetry and Thermal Gravimetric Analysis) revealed good stability of the two conjugates after exposure at temperatures close to 300 °C...
September 30, 2023: International Journal of Biological Macromolecules
https://read.qxmd.com/read/37746880/efficacy-and-safety-of-desmopressin-in-nocturia-and-nocturnal-polyuria-control-of-neurological-patients-a-systematic-review-and-meta-analysis
#16
REVIEW
Sakineh Hajebrahimi, Afra Darvishi, Reyhaneh HajEbrahimi, Nazli Asadi, Zahra Jafari Shendi, Negar Asiaban, Amirreza Naseri, Fatemeh Sadeghi-Ghyassi, Hadi Mostafaei, Hanieh Salehi-Pourmehr
PURPOSE: Evidence on the efficacy of desmopressin in nocturia in patients with neurological diseases is still very limited except for multiple sclerosis (MS). Our aim was to evaluate the efficacy and safety of desmopressin treatment on nocturia in patients with underlying neurological diseases. METHODS: Studies were identified by electronic search of PubMed, Embase, Cochrane, CINAHL, and Google Scholar databases. Studies were considered if they provided information on the effectiveness and safety of desmopressin (1-desamino-8-d-arginine vasopressin, or DDAVP) in the treatment of nocturia and their participants had acquired neurological pathology...
September 25, 2023: Neurourology and Urodynamics
https://read.qxmd.com/read/37736505/recent-progress-in-the-intranasal-plga-based-drug-delivery-for-neurodegenerative-diseases-treatment
#17
REVIEW
Nasim Aghaei Delche, Reyhaneh Kheiri, Behnam Ghorbani Nejad, Mojgan Sheikhi, Malihe Sadat Razavi, Milad Rahimzadegan, Zahra Salmasi
One of the most challenging problems of the current treatments of neurodegenerative diseases is related to the permeation and access of most therapeutic agents to the central nervous system (CNS), prevented by the blood-brain barrier (BBB). Recently, intranasal (IN) delivery has opened new prospects because it directly delivers drugs for neurological diseases into the brain via the olfactory route. Recently, PLGA-based nanocarriers have attracted a lot of interest for IN delivery of drugs. This review gathered clear and concise statements of the recent progress of the various developed PLGA-based nanocarriers for IN drug delivery in brain diseases including Alzheimer's, Parkinson's, brain tumors, ischemia, epilepsy, depression, and schizophrenia...
2023: Iranian Journal of Basic Medical Sciences
https://read.qxmd.com/read/37661637/increased-alpha-synuclein-and-neuroinflammation-in-the-substantia-nigra-triggered-by-systemic-inflammation-are-reversed-by-targeted-inhibition-of-the-receptor-for-advanced-glycation-end-products-rage
#18
JOURNAL ARTICLE
Daniel Oppermann Peixoto, Reykla Ramon Bittencourt, Juciano Gasparotto, Flávio Gabriel Carazza Kessler, Pedro Ozorio Brum, Nauana Somensi, Carolina Saibro Girardi, Lucas Dos Santos da Silva, Tiago Fleming Outeiro, José Cláudio Fonseca Moreira, Daniel Pens Gelain
The receptor for advanced glycation end products (RAGE) is a protein of the immunoglobulin superfamily capable of regulating inflammation. Considering the role of this receptor in the initiation and establishment of neuroinflammation, and the limited understanding of the function of RAGE in the maintenance of this condition, this study describes the effects of RAGE inhibition in the brain, through an intranasal treatment with the antagonist FPS-ZM1, in an animal model of chronic neuroinflammation induced by acute intraperitoneal injection of lipopolysaccharide (LPS)...
September 3, 2023: Journal of Neurochemistry
https://read.qxmd.com/read/37658972/nanovesicular-mediated-intranasal-drug-therapy-for-neurodegenerative-disease
#19
REVIEW
Shalu Singh, Rahul Shukla
Numerous neurodegenerative conditions, such as Alzheimer's, Huntington's, Parkinson's, amyotrophic lateral sclerosis, and glioblastoma multiform are now becoming significant concerns of global health. Formulation-related issues, physiological and anatomical barriers, post-administration obstacles, physical challenges, regulatory limitations, environmental hurdles, and health and safety issues have all hindered successful delivery and effective outcomes despite a variety of treatment options. In the current review, we covered the intranasal route, an alternative strategic route targeting brain for improved delivery across the BBB...
September 2, 2023: AAPS PharmSciTech
https://read.qxmd.com/read/37644374/retraction-note-intranasal-administration-of-endometrial-mesenchymal-stem-cells-as-a-suitable-approach-for-parkinson-s-disease-therapy
#20
Saeid Bagheri-Mohammadi, Behrang Alani, Mohammad Karimian, Rana Moradian-Tehrani, Mahdi Noureddini
No abstract text is available yet for this article.
August 29, 2023: Molecular Biology Reports
keyword
keyword
32825
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.